Table 2.
Type of myocardial infarction by clinical presentation
| ACS | CCS | ||||||
|---|---|---|---|---|---|---|---|
| Type of MI | Groups (N) |
Type of MI | Groups (N) |
||||
| Edoxaban | VKA | Total | Edoxaban | VKA | Total | ||
| Type 1 | 11 | 6 | 17 | Type 1 | 0 | 6 | 6 |
| Type 2 | 3 | 3 | 6 | Type 2 | 2 | 0 | 2 |
| Type 3 | 1 | 0 | 1 | Type 3 | 0 | 0 | 0 |
| Type 4aa | 0 | 0 | 0 | Type 4aa | 0 | 0 | 0 |
| Type 4b | 4 (4) | 4 (0) | 8 (4) | Type 4b | 3 (2) | 1 (0) | 4 (2) |
| Type 4c | 3 | 3 | 6 | Type 4c | 2 | 0 | 2 |
| Total | 22 | 16 | 38 | Total | 7 | 7 | 14 |
Type 4b denotes MI associated with stent thrombosis as detected by coronary angiography or autopsy in the setting of myocardial ischaemia in combination with a rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile URL. Depicted as N = total number (n = number from randomisation to 30 days).
a
Analysed according to the SCAI consensus definition.9